IP Library Granted Patent US 11,806,352
Granted Patent B2
US 11,806,352 · App. 13/697,578 · Granted Nov 7, 2023

Theobromine for increasing HDL-cholesterol

Inventors: Richard Draijer (AT Vlaardingen, NL); Bert-Jan Hendrik Van Den Born (AT Vlaardingen, NL)
Assignee: UPFIELD EUROPE B.V.
A61K31/522A23L33/105A23L33/11A23L33/12A61K31/56A61K45/06A23V2002/00
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 11,806,352
App. No.
13/697,578
Granted
Nov 7, 2023
Kind
B2
Abstract

Theobromine for use in the treatment of increasing HDL-cholesterol and/or increasing the ratio HDL-cholesterol:LDL-cholesterol in humans and the use of theobromine for increasing HDL-cholesterol in humans, and/or for increasing the ratio HDL-C/LDL-C, and compositions comprising theobromine.

Claims (49)

1. A method for increasing HDL-cholesterol in a human in need of treatment of increasing HDL-cholesterol, said method comprising:

administering to the human 300 to 2000 mg theobromine per day, wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water and 0.5% to 10% theobromine,

wherein at least a plant polyphenol is present in the emulsion, and the amount of the plant polyphenol is up to 500% based on the weight of the theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of the theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in HDL-cholesterol in humans in blood and/or serum is at least 5%.

2. The method of claim 1 , wherein said emulsion comprising, by weight, 2%-20% of the plant sterol.

3. The method of claim 1 , wherein the amount of the plant polyphenol in said emulsion is between 0% and 50% on the weight of the theobromine in the emulsion.

4. The method of claim 1 , wherein in the edible emulsion the water is in the amount of 70% by weight, the theobromine is in the amount of from 0.5% to 2% by weight, and the plant sterol and the theobromine are present in a weight ratio from 1:1 to 1:10.

5. The method of claim 4 , wherein the composition comprises from 85 to 99% by weight on the total composition of water.

6. The method of claim 4 , wherein the composition comprises from 0.4 to 1.5% by weight on the total composition of theobromine.

7. The method of claim 1 , wherein the administering step comprises administering an edible emulsion comprising theobromine, EPA, and DHA, wherein the weight ratio of theobromine:EPA and DHA combined is from 1:4 to 1:0.3.

8. The method of claim 1 , wherein the edible emulsion further comprising a statin, wherein the theobromine and the statin are present in a weight ratio from 200:1 to 5:1.

9. The method of claim 1 , wherein the edible emulsion further comprising a statin, wherein the theobromine and the statin are present, in a weight ratio from 100:1 to 10:1.

10. The method of claim 1 , wherein epicatechin is present in the emulsion and the weight ratio of the epicatechin: the theobromine is u 0.2:1.

11. The method of claim 1 , wherein the emulsion comprising a statin selected from the group consisting of atorvastatin, fluvastatin, lovastatin, pitavastatin, pravastatin, rosuvastatin, simvastatin, cerivastatin, mevastatin, and mixtures thereof.

12. The method of claim 1 , wherein administering to the human 750 to 1250 mg theobromine per day, and the administering step is performed for at least 5 days per week for at least 3 weeks.

13. A method for increasing the ratio HDL-cholesterol LDL-cholesterol in a human in need of treatment for improving blood lipids and/or blood lipids profile, said method comprising:

administering to the human 300 to 2000 mg theobromine per day,

wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water, and 0.5% to 10% theobromine,

wherein at least a plant polyphenol is present in the emulsion, and the amount of the plant polyphenol is up to 500% based on the weight of the theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of the theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in the ratio HDL-cholesterol LDL-cholesterol in humans in blood and/or serum is at least 5%.

14. A method for increasing the ratio HDL-cholesterol/non-HDL-cholesterol in a human in need of treatment for improving blood lipids and/or blood lipids profile, said method comprising:

administering to the human 300 to 2000 mg theobromine per day,

wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water, and 0.5% to 10% theobromine,

wherein at least a plant polyphenol is present in the emulsion, and the amount of the plant polyphenol is up to 500% based on the weight of the theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of the theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in the ratio HDL-cholesterol/non-HDL-cholesterol in humans in blood and/or serum is at least 5%.

15. A method for increasing HDL-cholesterol in a human in need of treatment of increasing HDL-cholesterol and having HDL-cholesterol level of 1.55 mmol/L or less, said method comprising:

administering to the human 300 to 2000 mg theobromine per day,

wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water, and 0.5% to 10% theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in HDL-cholesterol in humans in blood and/or serum is at least 5%.

16. A method for increasing the ratio HDL-cholesterol/LDL-cholesterol in a human in need of treatment for improving blood lipids and/or blood lipids profile and having an HDL-cholesterol level of 1.55 mmol/L or less, said method comprising:

administering to the human 300 to 2000 mg theobromine per day,

wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water, and 0.5% to 10% theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in the ratio HDL-cholesterol LDL-cholesterol in humans in blood and/or serum is at least 5%.

17. A method for increasing the ratio HDL-cholesterol/non-HDL-cholesterol in a human in need of treatment for improving blood lipids and/or blood lipids profile and having an HDL-cholesterol level of 1.55 mmol/L or less, said method comprising:

administering to the human 300 to 2000 mg theobromine per day,

wherein the theobromine is administered in an edible emulsion comprising, by weight, 20% to 85% of oil, 15% to 80% water, and 0.5% to 10% theobromine,

wherein the emulsion further comprises a plant sterol, and a weight ratio of the theobromine: the plant sterol is from 0.3:1 to 1:1,

wherein the emulsion further comprises EPA and DHA, and a weight ratio of the theobromine: the combined weight of EPA and DHA is from 1:2 to 1:0.5, and

wherein the increase in the ratio HDL-cholesterol/non-HDL-cholesterol in humans in blood and/or serum is at least 5%.

Assignments (4)
CHANGE OF NAME Recorded Jun 15, 2020
From: UPFIELD US INC.
To: UPFIELD EUROPE B.V.
Reel/Frame 052938/0715 →
CHANGE OF NAME Recorded Sep 27, 2018
From: UNILEVER BCS US INC.
To: UPFIELD US INC.
Reel/Frame 047158/0449 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Apr 5, 2017
From: CONOPCO, INC., D/B/A UNILEVER
To: UNILEVER BCS US, INC.
Reel/Frame 042166/0596 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Feb 4, 2013
From: DRAIJER, RICHARD; VAN DEN BORN, BERT-JAN HENDRIK
To: CONOPCO, INC., D/B/A UNILEVER
Reel/Frame 029745/0613 →
Priority Claims (1)
EP 10163276 · May 19, 2010 · regional
Continuity (1)
Related Publication 20130116221A1 · May 9, 2013